Climb Bio, Inc. (CLYM)
NASDAQ: CLYM · Real-Time Price · USD
1.250
-0.050 (-3.85%)
Apr 25, 2025, 4:00 PM EDT - Market closed

Company Description

Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies for immune-mediated diseases.

The company develops budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases.

It is also developing budoprutug IV for the treatment of primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus.

In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN).

The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024.

Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.

Climb Bio, Inc.
Climb Bio logo
Country United States
Founded 2018
IPO Date Aug 10, 2021
Industry Biotechnology
Sector Healthcare
Employees 18
CEO Aoife Brennan

Contact Details

Address:
20 William Street, Suite 145
Wellesley Hills, Massachusetts 02481
United States
Phone 866 857 2596
Website climbbio.com

Stock Details

Ticker Symbol CLYM
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001768446
ISIN Number US28658R1068
Employer ID 83-2273741
SIC Code 2834

Key Executives

Name Position
Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc Chief Executive Officer, President and Director
Dr. Brett Kaplan M.B.A., M.D. Chief Operating Officer and Principal Financial Officer
Emily Pimblett CPA Senior Vice President of Finance and Chief Accounting Officer
Dr. Nishi Rampal M.D. Senior Vice President of Clinical Development
Janaki M. Subramanyam M.Sc. Vice President and Head of Regulatory Affairs
Kate Hecht M.B.A. Senior Vice President of Program Management
Dr. Perrin Wilson B.S., Ph.D. Chief Business Officer

Latest SEC Filings

Date Type Title
Apr 25, 2025 ARS Filing
Apr 25, 2025 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 25, 2025 DEF 14A Other definitive proxy statements
Apr 1, 2025 S-8 Securities to be offered to employees in employee benefit plans
Apr 1, 2025 8-K Current Report
Mar 25, 2025 8-K Current Report
Mar 25, 2025 424B5 Filing
Mar 25, 2025 10-K Annual Report
Feb 13, 2025 SCHEDULE 13G/A Filing
Jan 10, 2025 8-K Current Report